Close
Close

pCDCAR1 MUC1 h(28ζ) (CAR-0120ZP3439)

 Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-MUC1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human MUC1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-MUC1 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Colorectal cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • MUC1
  • Targeting Cell Type
  • T Cell
  • Targeting Diseases
  • Colorectal cancer
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-CD28-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide costimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • TAB-004
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • mucin 1, cell surface associated
  • Synonyms
  • EMA; MCD; PEM; PUM; KL-6; MAM6; MCKD; PEMT; CD227; H23AG; MCKD1; MUC-1; ADMCKD; ADMCKD1; CA 15-3; MUC-1/X; MUC1/ZD; MUC-1/SEC; M3A1

Customize Your CAR Products

Customize Your CAR Products
Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Increased MUC28z positivity on activated human PBMC.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.1 Increased MUC28z positivity on activated human PBMC.

MUC28z CAR expression in activated human T cells after retrovirus transduction, as determined by flow cytometry analysis of Myc-tag expression. Cells were gated for CD4 or CD8, and then analyzed for Myc-tag expression. Dead cells were excluded by 7-AAD staining.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.2 Flow cytometry analysis of cells expressing tMUC1, determined by TAB004.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.2 Flow cytometry analysis of cells expressing tMUC1, determined by TAB004.

Percentage of cells expressing tMUC1, determined by TAB004-APC/Cy5.5 staining and flow cytometry.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.3 The MUC28z CAR T cells lyse TNBC tumor cells in vitro in an antigen-dependent manner.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.3 The MUC28z CAR T cells lyse TNBC tumor cells in vitro in an antigen-dependent manner.

Percentage of TNBC tumor cell lysis by MUC28z CAR T cells. Cells were co-cultured at E:T ratio of 5:1 for 3 days. The lysis of tumor cells was determined by MTT assay.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.4 MUC28z CAR T cells show significant difference in cell surface marker expressions in vitro..

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.4 MUC28z CAR T cells show significant difference in cell surface marker expressions in vitro..

The expression of the indicated surface markers on MUC28z CAR T cells was determined by flow cytometry on day 14 after retrovirus transduction. Cells were gated on CD8+ T cells.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.5 CD8+ MUC28z CAR T cells produced IFN-γ and increased Granzyme B in response to tMUC1 high HCC70 cells in vitro.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.5 CD8+ MUC28z CAR T cells produced IFN-γ and increased Granzyme B in response to tMUC1 high HCC70 cells in vitro.

MUC28z CAR T cells were co-cultured with HCC70 tumor cells for 24 h, and then cells were stained intracellularly for IFN-γ and Granzyme B in addition to Myc-tag. Cells were gated on CD8+ T cells, followed by flow cytometry analysis.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.6 MUC28z CAR T cells produced IFN-γ in response to tMUC1-expressing TNBC in vitro.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.6 MUC28z CAR T cells produced IFN-γ in response to tMUC1-expressing TNBC in vitro.

T cells were co-cultured with the selected tumor cell lines (E:T = 2:1) for 24 h, and then the culture supernatants were assayed for IFN-γ by ELISA.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.7 The lysis of HCC70 cells by MUC28z CAR T cells was partially reversed by IFN-γ neutralization.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.7 The lysis of HCC70 cells by MUC28z CAR T cells was partially reversed by IFN-γ neutralization.

HCC70 cells were co-cultured with MUC28z CAR T cells for 24 h in the absence or presence of IFN-γ neutralizing antibody. The lysis of HCC70 cells was determined by MTT assay.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.8 MUC28z CAR T cells released a large panel of cytokines after tMUC1-specific cell activation.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.8 MUC28z CAR T cells released a large panel of cytokines after tMUC1-specific cell activation.

T cells were co-cultured with HCC70 cells (E:T = 2:1) for 24 h, and then the culture supernatants were assayed for cytokine concentration by human cytokine array.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.9 HCC70 tumor growth reduction by a single injection of MUC28z CAR T cells in vivo.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.9 HCC70 tumor growth reduction by a single injection of MUC28z CAR T cells in vivo.

HCC70 cells were orthotopically injected into the mammary fat pad of female NSG mice. When tumors were palpable, mice were randomized and received a single i.v. injection MUC28z CAR T cells on day 4 post-tumor cell challenge. Tumor growth was monitored by caliper measurement.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.10 The wet weight of resected tumor mass on day 57 at endpoint.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.10 The wet weight of resected tumor mass on day 57 at endpoint.

Top is the tumor pictures at the endpoint. The weights of individual tumors are presented.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.11 Increase of activation/exhaustion markers on CD8+ MUC28z CAR T cells.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.11 Increase of activation/exhaustion markers on CD8+ MUC28z CAR T cells.

MUC28z CAR T cells were stained right before i.v. injection and right after tumor infiltrating lymphocytes analysis from tumor mass. Cells were gated on CD8+ T cells.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.12 MUC28z CAR T cells have long-term efficacy for HCC70 tumor reduction in vivo.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.12 MUC28z CAR T cells have long-term efficacy for HCC70 tumor reduction in vivo.

Decrease of HCC70 tumor burden by a single injection of MUC28z CAR T cells in vivo. HCC70 tumor were inoculated as described in Figure 9.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.13 MUC28z CAR T cells have long-term efficacy for HCC70 tumor reduction in vivo.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.13 MUC28z CAR T cells have long-term efficacy for HCC70 tumor reduction in vivo.

No tumor antigen loss while MUC28z CAR T cells were present in vitro. HCC70 cells were cultured alone or co-cultured with the mock T cells or MUC28z CAR T cells (E:T = 2:1) for 24 h. The viable HCC70 cells were analyzed for tMUC1 level.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.14 MUC28z CAR T cells have long-term efficacy for HCC70 tumor reduction in vivo.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.14 MUC28z CAR T cells have long-term efficacy for HCC70 tumor reduction in vivo.

Increased intensity of tMUC1 expression in MUC28z CAR T cells-treated HCC70 tumors. HCC70 tumor sections were prepared on day 81 at endpoint. IHC staining of tMUC1 was performed with TAB004 antibody. The brown staining shows tMUC1 positivity.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.15 Blocking PD1 enhanced the cytolytic response of MUC28z CAR T cells in vitro.

CAR Construction : TAB004 scfv-41BB-CD3ζ Latest CAR Construction

Fig.15 Blocking PD1 enhanced the cytolytic response of MUC28z CAR T cells in vitro.

HCC70 cells were co-cultured with MUC28z CAR T cells at E:T ratio of 2:1 for 24 h in the absence or presence of PD1 blocking antibody. The lysis of HCC70 cells was determined by MTT assay.

Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology, 10, 1149.
Complete CAR data Funcs

Fig.16 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with tumor cell after for 72 h.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.16 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with tumor cell after for 72 h.

Uninfected, CTL or CAR T cells were exposed to indicated PDA cell lines for 72 hrs at T:E 1:10, and survival level of PDA cells were measured using MTT assay.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.17 Intracellular IFN-γ detection in mock and CAR T cells before and after exposure to PDA cells for 24 hrs at T:E 1:10.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.17 Intracellular IFN-γ detection in mock and CAR T cells before and after exposure to PDA cells for 24 hrs at T:E 1:10.

Percentage of CD4+ and CD8+ CAR T cells that are positive for IFN-γ was measured by flowcytometry.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.18 Intracellular perforin detection in mock and CAR T cells before and after exposure to PDA cells for 24 hrs at T:E 1:10.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.18 Intracellular perforin detection in mock and CAR T cells before and after exposure to PDA cells for 24 hrs at T:E 1:10.

Percentage of CD4+ and CD8+ CAR T cells that are positive for perforin was measured by flowcytometry.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
CAR scFv data FCM

Fig.19 Surface MUC1 expression in a panel of PDA cell lines detected by TAB004 staining.

CAR Construction : Latest CAR Construction

Fig.19 Surface MUC1 expression in a panel of PDA cell lines detected by TAB004 staining.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.20 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with 9 PDA cell lines by MTT assay.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.20 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with 9 PDA cell lines by MTT assay.

Cancer cells are ordered from low to high MUC1 (left to right). HPDE cell was used as normal control cell line. All PDA cells show significant reduction in survival after treated with CAR T cells. T:E ratio of 1:10 and 72 hrs incubation was applied to all cell lines.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.21 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with BxPC3-Neo and BxPC3-MUC1 for 72 hrs.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.21 In vitro antitumor efficacy of CAR-MUC1 T cells co-culture with BxPC3-Neo and BxPC3-MUC1 for 72 hrs.

The percentage survival of BxPC3-Neo and BxPC3-MUC1 treated with CAR T cells for 72 hrs at T:E ratio of 1:5. BxPC3-Neo stays intact when treated with low dose of CAR T cells (T:E 1:5), while BxPC3-MUC1 is effectively killed.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Cyt

Fig.22 Spontaneous killing of BxPC3-MUC1 cells by CAR T cells within 24hours measured by an LDH-based technique, Cytotox assay.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.22 Spontaneous killing of BxPC3-MUC1 cells by CAR T cells within 24hours measured by an LDH-based technique, Cytotox assay.

CAR T cells show significantly higher level of cytotoxicity against BxPC3-MUC1 cells compared to BxPC3-Neo cells.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.23 Tumor killing analysis of PDA cells and normal pancreatic epithelial cell line (HPDE) when treated with different dose of CAR T cells.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.23 Tumor killing analysis of PDA cells and normal pancreatic epithelial cell line (HPDE) when treated with different dose of CAR T cells.

Data shows that CAR T cell killing is dose dependent. By increasing the dose of CAR T cells, more killing is observed in PDA cells, while the survival of normal cell (HPDE) even at T:E of 1:20 stays unchanged.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.24 Killing analysis of a panel of human normal primary cells treated with CAR T cells for 72 hrs at T:E 1:10.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.24 Killing analysis of a panel of human normal primary cells treated with CAR T cells for 72 hrs at T:E 1:10.

The percentage survival of a panel of human normal primary cells including fibroblasts and breast epithelial cells obtained from healthy donors treated with CAR T cells for 72 hrs at T:E 1:10.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.25 tMUC1-CAR-T cells produce IFN-γ upon activation and antigen recognition.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.25 tMUC1-CAR-T cells produce IFN-γ upon activation and antigen recognition.

The amount of released IFN-γ in the co-culture media of CAR T cells and cancer cells measured by sandwich ELISA.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.26 tMUC1-CAR-T cells produce granzyme B upon activation and antigen recognition.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.26 tMUC1-CAR-T cells produce granzyme B upon activation and antigen recognition.

The amount of released granzyme B in the co-culture media of CAR T cells and cancer cells measured by sandwich ELISA.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.27 tMUC1-CAR T cells control pancreatic tumor growth in vivo.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.27 tMUC1-CAR T cells control pancreatic tumor growth in vivo.

Images of the tumors harvested from mice treated with mock T or CAR T cells on day 68 post tumor inoculation (top). Tumor wet weights of the mice treated with mock T or CAR T cells on day 68 after tumor inoculation (bottom).

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.
Complete CAR data Funcs

Fig.28 Visual representation of CAR T cells trafficking in the pancreatic tumors.

CAR Construction : TAB004 scfv-CD28-CD3ζ Latest CAR Construction

Fig.28 Visual representation of CAR T cells trafficking in the pancreatic tumors.

To evaluate T cells trafficking into the fibrotic pancreatic tumor, six tumor bearing mice (day 52 post-surgery) were injected IV with either 4e6 vivotrack-680 labeled-CAR T cellse. After 24 hrs, mice were scarified and tumors were harvested and imaged using fluorescent channel on IVIS machine.

Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., ... & Mukherjee, P. (2019). Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells, 8(9), 1070.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-MUC1 (TAB-004) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-0120ZP3439). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

CAR Vector Products

CAR Cell Products

CAR Viral Particles

CAR Animal Cells

CAR-MA Cell Products

CAR-MA Vector Products

CAR mRNA

TriCAR Vector Products

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout